Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loteprednol etabonate for inflammation and pain after cataract surgery
NCT01060072Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Feb 2010
- Primary completion
- Sep 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of loteprednol etabonate ophthalmic gel 0.38% in post-operative inflammation and postoperative pain (2 arms), sponsored by Bausch + Lomb. Primary endpoints: Resolution of Anterior Chamber Cells at Day 8 and Grade 0 Pain at Day 8. Started Feb 2010; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
post-operative inflammationpostoperative pain
Beyond the preview
Go deeper on NCT01060072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01060072.